trending Market Intelligence /marketintelligence/en/news-insights/trending/3d7tdqx1KsezZCqzR6ZBcQ2 content esgSubNav
In This List

Quidel's antepartum diagnostic test gets US FDA clearance

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Quidel's antepartum diagnostic test gets US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Quidel Corp.'s Solana GBS Assay test, which detects Group B streptococcus in women nearing childbirth.

The bacteria can cause infections leading to sepsis, pneumonia and meningitis in newborns. Deafness and developmental disabilities may also result from the transmission Group B streptococcus at delivery.